LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Blood sugar levels last night at an all time low for me of 4.8. This morning 5.6 setting a new low average of 5.8 over 7days, 6.0 over 14 days and 6.2 over 30 days. I think I'm going to have to watch that the reading doesn't go too low!

good stuff kim - hope the reading keeps steady for you - i know people in similar situations

Thanks gibby.

you are welcome & :

http://www.dailymail.co.uk/news/article-1220169/Actimel-advert-banned-claiming-yoghurt-drink-prevents-illness.html#comments

comment from above link / article: 'Again, Provexis with Fruitflow is currently the only holder of an Article 13.5 Approval from the EFSA which is what all these big manufacturers have been seeking (along with article 13.1 claims as well)'

good for pxs imo

Incidentally, I heard a snippet on the news today that Danone are having to omit one of the claims they are making about their yogurt because they are unsubstantiated. I'm sure similar rulings will soon follow - all to Provexis' advantage.

The new shares are about to hit the market and probably the sp will dip. IMO as news gets closer those in the know will start piling in and we'll be shooting up again! I hope so.

MP - first tranche of new shares are already 'in' the market, 2nd tranche should get approval on friday 14th Oct for admittance onto market "before the end of October"

so couple of weeks probably before PXS have a billion shares in issue. we still have to see if we get our chance too.

thanks GN in that case we are holding up quite well.

Tried a couple of days of eating junk food, drinking wine and beer, basically doing what I shouldn't! B/s readings 6.5 yesterday, 6.4 today; they would normally have been in excess of 9. I am impressed!

not taking Actimel as well i assume!

No, Danone have been telling porkies, I only stick to the stuff that really works! ;o)

Although, if you mean to categorise it in the junk food label, maybe I should give it a go!!

at least the Actimel story tells me why it is taking so long for PVX to get "the wording approval" ...... seems to me, that what they actually have to do is come up with some pretty persuasive evidence that Fruitflow does what they claim, so it could all be 6/12 months away - and that assumes they get the nod.

am i wrong, comme d'habitude?

Surely you aren't always wrong? :o) But in this case half wrong! Fruitflow is already approved as doing what it claims; the wording to go on the box is still being worked on, though I don't know why it is taking so long.

then why do all these trials continue - e.g. per the one whose results were announced the other day?

cynic will it do what it says on the tin,as always sell on the actual news?

if it does what it says on the tin, then just maybe that wise adage will not prove correct in this instance - i don't have a significant holding anyway

Cynic, the present ongoing trials are separate to the Fruitflow addition to Sirco, it is the wording that is presently on the Sirco carton is that is under review.

I would like to think that there will be many more lines that Fruitflow can follow in addition to the Asprin trials.

Fruitflow is not the only string to the Provexis bow, it will be interesting to see how the company develops and although the clinical trial for its NSP#3G plantain medical food for Crohns disease patients is in it's infancy, it already shows promise.

I wonder where the sp will end up tomorrow after the addition of the new shares?!

the crohn's treatment is years into the future .... even the very first human trials won't be completed for another 18 months

By which time PXS sp will be anything between nil and 5,000!
;o)